WAKEFIELD, Mass.--(BUSINESS WIRE)--Protein Dynamic Solutions LLC (PDS), developer of breakthrough technologies for structural characterization of therapeutic proteins, was recognized by Business Insider for provision of instruments and contract research services to the biopharmaceutical industry.
The listing was researched and compiled by PitchBook and represented in their infographic on the most valuable VC-backed company in each US state.
PDS was founded in the US bioprocessing hub of Puerto Rico by industry veterans and recently relocated to the Greater Boston area with establishment of head office, research and operations in Wakefield, Massachusetts. The company provides advanced critical quality attribute (CQA) and comparability testing through CRO services that include aggregation, stability and higher order structure analysis. PDS also provides cutting edge spectroscopy instrumentation for clonal selection, formulation optimization and release/comparability testing.
“We are delighted to be recognized in this esteemed listing and to serve the biopharmaceutical industry across both innovator and biosimilar value chains,” said Dr. Belinda Pastrana, CEO. “Our new location places us at the heart of the world’s leading life sciences supercluster, where we enjoy proximity to our clients and membership of valuable organizations such as MassBIO and ALDA.”
PDS’ flagship platform uses a unique combination of laser-microscopy and molecular spectrometry to provide array-based analysis of up to 24 samples simultaneously for direct comparison of clones, formulations or other factors over a range of stressor conditions such as ramped temperature or agitation. In addition to informing critical quality attributes such as aggregation, the platform enables comparability testing following process changes and has been demonstrated for biosimilarity testing, including use by innovator pharma companies to extend their patent protection.
About Protein Dynamic Solutions (PDS):
PDS provides breakthrough tools and services for bioanalysis of therapeutic candidates. The PDS team, Board members and advisors are veterans of biopharma and the life sciences with a strong track record for realizing cutting-edge technologies.